Approval Alert: Biogen/Eisai’s Leqembi® (lecanemab) Approved by NMPA to Treat Alzheimer’s Disease
Biogen and Eisai announced that Leqembi® (lecanemab) has been approved by the National Medical Products Administration (NMPA) in China for the…
Pearce IP is Australia and New Zealand’s leading life sciences-focused intellectual property law firm.
Supporting life sciences clients from early-stage R&D through to commercial launch and beyond.
pearceIP.law | [email protected] | +61 2 9023 9988 | +64 4 886 1199
Popular articles from this firm
